



## INFORMAZIONI PERSONALI

## MASSIMO CARLO MAURI



3355932220

Email aziendale

massimo.mauri@policlinico.mi.it

Sesso Maschio

Data di Nascita

07/09/1957

Nazione

ITALIA

## POSIZIONE RICOPERTA

DIRIGENTE MEDICO

## ESPERIENZA PROFESSIONALE

Da Settembre 1990 a Dicembre 2017

MEDICO PSICHIATRA

FONDAZIONE IRCCS CA' GRANDA, OSPEDALE MAGGIORE POLICLINICO MILANO

DIRIGENTE 1 LIVELLO

RESPONSABILE SERVIZIO DI PSICOFARMACOLOGIA CLINICA (Incarico Professionale di Servizio, IPS)

Attività o Settore

PSICHIATRIA

Da Gennaio 1989 a Aprile 1990

MEDICO PSICHIATRA

Ex USSL 13 MARIANO COMENSE (CO)

AIUTO CORRESPONSABILE OSPEDALIERO PSICHIATRA

Attività o Settore

PSICHIATRIA

## ISTRUZIONE E FORMAZIONE

Da Giugno 2005 a Luglio 2005

Post Graduate Course, Update on Schizophrenia, Bipolar Disorder and Depression

Boston University School of Medicine, Boston, Massachusetts

Da Maggio 2002 a Maggio 2002

Post Graduate Course, Advanced Course on Schizophrenia

The Karolinska Institute NEUROTEC, Department of Psychiatry, Huddinge University Hospital, Stockholm

Da Maggio 1998 a Maggio 1998

Post Graduate Course on Psychiatry

Psychiatric Institute of Washington, National Institute of Mental Health (NIMH), Clinical Brain Disorder Branch (DIRP), Washington DC

Da Aprile 1995 a Aprile 1995

Post Graduate Course on Schizophrenia

The Karolinska Institute, Department of Clinical Neuroscience, Stockholm

Fino al 1976

MATURITA' SCIENTIFICA

LICEO SCIENTIFICO ALESSANDRO VOLTA

Fino al 1982

LAUREA IN MEDICINA E CHIRURGIA

UNIVERSITA' DI MILANO



## ISTRUZIONE E FORMAZIONE

Fino al 1986 SPECIALISTA IN PSICHIATRIA  
UNIVERSITA' DI MILANO

Fino al 1990 DOTTORATO DI RICERCA IN PSICHIATRIA E SCIENZE RELAZIONALI  
UNIVERSITA' DI MILANO

## COMPETENZE PERSONALI

Lingua madre Italiano

Altre lingue

	COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
Inglese	B2	C1	B2	C1	C1

Livelli: A 1/2 Livello Base - B 1/2 Livello Intermedio - C 1/2 Livello Avanzato

Quadro Comune Europeo di Riferimento delle Lingue

Competenze organizzative e gestionali

Responsabile del Servizio di Diagnosi e Cura (SPDC) dell'Unita' Operativa Psichiatrica dell' IRCCS Ospedale Maggiore di Milano dal 2001 al 2006.

Responsabile CPS 1 (Milano centro) dal giugno 2015

Responsabile del Servizio di Psicofarmacologia Clinica (Incarico Professionale di Servizio)(IPS) già Laboratorio di Neuropsicofarmacologia Clinica, dal 1995

Referente responsabile del CPS di Zona 10 da Aprile a Giugno 2013, CPS Zona 13 da Giugno a Dicembre 2014

Competenze professionali

Reviewer di diverse riviste internazionali: Schizophrenia Research, Acta Psychiatr Scand, Expert Opinion in Psychiatry, J Clin Psychopharmacol, Pharmacopsychiatry, Progress in Neuropsychopharmacol & Biol Psychiatry, CNS Drugs, Clinical Pharmacokinetics, Drugs & Aging, Clinical Drug Investigation, Clinical Practice & Epidemiology in Mental Health, Psychopharmacology (Berl), Advances in Therapy

Ha svolto attività didattiche nell'ambito del Corso di Clinica Psichiatrica e di Neuropsichiatria Geriatrica del corso di studi in Medicina e Chirurgia.

Dal 1990 al 1996 e' stato docente della Scuola per Infermieri professionale della Croce Rossa Italiana (Milano) come titolare dell'insegnamento di Psichiatria.

Svolge l'attività di "tutor" nell'ambito del Corso di Medicina e Chirurgia e della Scuola di Specializzazione in Psichiatria dal 1993.

E' stato correlatore di diverse tesi di laurea presentate presso la Facoltà di Medicina e Chirurgia dell'Università di Milano.

Dal 2000 al 2015 Professore a Contratto della Scuola di Specialità in Psichiatria dell' Università degli Studi di Milano.

Dall'Anno Accademico 1995 e' Professore a Contratto dell' Università degli Studi di Milano per il Corso di Laurea in Tecnica della Riabilitazione Psichiatrica, già Diploma Universitario di Riabilitazione Psichiatrica e Psicosociale.

Competenze informatiche

Utilizzo Programmi di Statistica Medica (Statgraphics, SPSS)

Microsoft Office (PC e MAC)

Patente di guida

A

## ULTERIORI INFORMAZIONI

Appartenenza a gruppi/associazioni

Società Italiana di Psichiatria (SIP) dal 1985; Sezione Regionale Lombarda della SIP dal 1989; Società Italiana di Psicopatologia dal 2010; Società Italiana di Neuropsicofarmacologia dal 2010; European College of Neuropsychopharmacology (ECNP) dal 1994; International Member American Psychiatric Association (APA) dal 1999; Member WPA Section on Pharmacopsychiatry dal 2010

Pubblicazioni

Digitare sul sito internazionale : www.pubmed.com: "mauri mc"

Riconoscimenti e premi

"International Award" Charing Cross and Westminster Medical School (University of London) (1990); Premio Eustachio Zara del Centro Studi Sen. Leonardo Bianchi (1993)

## ALLEGATI

Pubblicazioni censite da PubMed ( United States National Library of Medicine)

Dati personali

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 'Codice in materia di protezione dei dati personali'.

1: Mauri MC, Di Pace C, Reggiori A, Paletta S, Colasanti A. Primary psychosis with comorbid drug abuse and drug-induced psychosis: Diagnostic and clinical evolution at follow up. *Asian J Psychiatr.* 2017 Oct;29:117-122. doi: 10.1016/j.ajp.2017.04.014. Epub 2017 May 2. PubMed PMID: 29061407.

2: Rovera C, Mauri MC, Di Pace C, Paletta S, Reggiori A, Ciappolino V, Cattaneo D, Baldelli S, Clementi E, Altamura AC. Effect of N-Desalkylquetiapine/Quetiapine Plasma Level Ratio on Anxiety and Depression in Bipolar Disorder: A Prospective Observational Study. *Ther Drug Monit.* 2017 Aug;39(4):441-445. doi: 10.1097/FTD.0000000000000413. PubMed PMID: 28486308.

3: Mauri MC, Paletta S, Di Pace C, Reggiori A, Rovera C, Fiorentini A, Altamura CA. Paliperidone Long-Acting Plasma Level Monitoring and a New Method of Evaluation of Clinical Stability. *Pharmacopsychiatry.* 2017 Jul;50(4):145-151. doi: 10.1055/s-0037-1601396. Epub 2017 Mar 9. PubMed PMID: 28278537.

4: Altamura AC, Delvecchio G, Paletta S, Di Pace C, Reggiori A, Fiorentini A, Mirabile MD, Paoli RA, Cinnante C, Triulzi F, Mauri MC, Brambilla P. Gray matter volumes may predict the clinical response to paliperidone palmitate long-acting in acute psychosis: A pilot longitudinal neuroimaging study. *Psychiatry Res.* 2017 Mar 30;261:80-84. doi: 10.1016/j.psychres.2017.01.008. Epub 2017 Jan 26. PubMed PMID: 28161644.

5: Mauri MC, Reggiori A, Paletta S, Di Pace C, Altamura AC. Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation. *Expert Opin Drug Saf.* 2017 Mar;16(3):365-379. doi: 10.1080/14740338.2017.1288716. Epub 2017 Feb 9. Review. PubMed PMID: 28140680.

6: Rovera C, Cremaschi L, Thanju A, Fiorentini A, Mauri MC, Serati M, Lindenmayer JP, Altamura AC. Cabergoline can induce mania with psychotic features in bipolar

I disorder: a case report. *Asian J Psychiatr.* 2016 Aug;22:94–5. doi: 10.1016/j.ajp.2016.05.010. Epub 2016 May 24. PubMed PMID: 27520906.

7: Rovera C, Mauri MC, Bertin E, Di Pace C, Paletta S, Reggiori A, De Gaspari IF, Cattaneo D, Mari D, Altamura AC. Duloxetine in elderly major depression disorder: effectiveness and drug plasma level evaluation. *Hum Psychopharmacol.* 2016 Sep;31(5):349–55. doi: 10.1002/hup.2544. Epub 2016 Jul 12. PubMed PMID: 27400882.

8: Parabiaghi A, Tettamanti M, D'Avanzo B, Barbato A; GiSAS study group. Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. *Acta Psychiatr Scand.* 2016 Jan;133(1):63–75. doi: 10.1111/acps.12468. Epub 2015 Aug 7. PubMed PMID: 26252780.

9: Mauri M, Mauri MC, Adami M, Reggiardo G, Giulio C. Efficacy and tolerability of paliperidone ER in patients with unsatisfactorily controlled schizophrenia by other antipsychotics: a flexible-dose approach. *Int Clin Psychopharmacol.* 2015 Nov;30(6):329–37. doi: 10.1097/YIC.000000000000092. PubMed PMID: 26230269; PubMed Central PMCID: PMC4650983.

10: Mauri MC, Maffini M, Di Pace C, Reggiori A, Paletta S, Moliterno D, Rovera C, Altamura CA. "Long-acting" olanzapine in maintenance therapy of schizophrenia: A study with plasma levels. *Int J Psychiatry Clin Pract.* 2015 Jun;19(2):99–105. doi: 10.3109/13651501.2014.1000928. PubMed PMID: 25547438.

11: Dragogna F, Mauri MC, Marotta G, Armao FT, Brambilla P, Altamura AC. Brain metabolism in substance-induced psychosis and schizophrenia: a preliminary PET study. *Neuropsychobiology.* 2014;70(4):195–202. doi: 10.1159/000366485. Epub 2014 Nov 27. PubMed PMID: 25471704.

12: Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, Rucci P, Gibertoni D, Aguglia E, Amore M, Bellomo A, Biondi M, Brugnoli R, Dell'Osso L, De Ronchi D, Di Emidio G, Di Giannantonio M, Fagiolini A, Marchesi C, Monteleone P, Oldani L, Pinna F, Roncone R, Sacchetti E, Santonastaso P, Siracusano A, Vita A, Zeppegno P, Maj M; Italian Network For Research on Psychoses. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. *World Psychiatry*. 2014 Oct;13(3):275-87. doi: 10.1002/wps.20167. PubMed PMID: 25273301; PubMed Central PMCID: PMC4219069.

13: Mauri MC, Fiorentini A, Paletta S, Altamura AC. Pharmacokinetics of antidepressants in patients with hepatic impairment. *Clin Pharmacokinet*. 2014 Dec;53(12):1069-81. doi: 10.1007/s40262-014-0187-5. Review. PubMed PMID: 25248846.

14: Mauri MC, Paletta S, Colasanti A, Misericocchi G, Altamura AC. Clinical and neuropsychological correlates of major depression following post-traumatic brain injury, a prospective study. *Asian J Psychiatr*. 2014 Dec;12:118-24. doi: 10.1016/j.ajp.2014.07.003. Epub 2014 Aug 18. PubMed PMID: 25193507.

15: Aguglia E, Biggio G, Signorelli MS, Mencacci C; Steering Committee on behalf of the STIMA-D Investigators. Italian Study on Depressive Disorders (STudio Italiano MAIattia Depressiva, or STIMA-D): a nationwide snapshot of the status of treatment for major depression. *Pharmacopsychiatry*. 2014 May;47(3):105-10. doi: 10.1055/s-0034-1375628. Epub 2014 May 20. PubMed PMID: 24846085.

16: Buoli M, Mauri MC, Altamura AC. Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder. *Expert Opin Drug Metab Toxicol*. 2014 Jun;10(6):885-92. doi: 10.1517/17425255.2014.907794. Epub 2014 Apr 9.

Review. PubMed PMID: 24717138.

17: Mauri MC, Paletta S, Maffini M, Colasanti A, Dragogna F, Di Pace C, Altamura AC. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J. 2014 Oct 13;13:1163–91. eCollection 2014. Review. PubMed PMID: 26417330; PubMed Central PMCID: PMC4464358.

18: Rovera C, Curti R, Colombo EM, Zappa MA, Lattuada E, Mozzi E, Mauri MC, Roviario G, Altamura AC. [Psychiatric features before and after intervention: a study of patients affected by severe obesity undergoing adjustable gastric banding]. Riv Psichiatr. 2013 Sep–Oct;48(5):393–9. doi: 10.1708/1356.15066. Italian. PubMed PMID: 24326752.

19: Altamura AC, Bertoldo A, Marotta G, Paoli RA, Caletti E, Dragogna F, Buoli M, Baglivo V, Mauri MC, Brambilla P. White matter metabolism differentiates schizophrenia and bipolar disorder: a preliminary PET study. Psychiatry Res. 2013 Dec 30;214(3):410–4. doi: 10.1016/j.psychresns.2013.08.011. Epub 2013 Oct 18. PubMed PMID: 24144506.

20: Mauri MC, Paletta S, Maffini M, Moliterno D, Altamura AC. Suicide attempts in schizophrenic patients: clinical variables. Asian J Psychiatr. 2013 Oct;6(5):421–7. doi: 10.1016/j.ajp.2013.07.001. Epub 2013 Aug 2. PubMed PMID: 24011691.

21: Altamura AC, Moliterno D, Paletta S, Maffini M, Mauri MC, Bareggi S. Understanding the pharmacokinetics of anxiolytic drugs. Expert Opin Drug Metab Toxicol. 2013 Apr;9(4):423–40. doi: 10.1517/17425255.2013.759209. Epub 2013 Jan 21. Review. PubMed PMID: 23330992.

22: Altamura AC, De Gaspari IF, Rovera C, Colombo EM, Mauri MC, Fedele L. Safety of SSRIs during pregnancy: a controlled study. Hum Psychopharmacol.

2013

Jan;28(1):25-8. doi: 10.1002/hup.2276. Epub 2012 Nov 20. PubMed PMID: 23166037.

23: Altamura AC, Moliterno D, Paletta S, Buoli M, Dell'osso B, Mauri MC, Bareggi SR. Effect of quetiapine and norquetiapine on anxiety and depression in major psychoses using a pharmacokinetic approach: a prospective observational study. Clin Drug Investig. 2012 Mar 1;32(3):213-9. doi: 10.2165/11597330-000000000-00000. PubMed PMID: 22299714.

24: Fiorentini A, Volonteri LS, Dragogna F, Rovera C, Maffini M, Mauri MC, Altamura CA. Substance-induced psychoses: a critical review of the literature. Curr Drug Abuse Rev. 2011 Dec;4(4):228-40. Review. PubMed PMID: 21999698.

25: Altamura AC, Buoli M, Mauri MC. Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia: a 4-year follow-up naturalistic study. J Clin Psychopharmacol. 2011 Oct;31(5):661-3. doi: 10.1097/JCP.0b013e31822c989a. PubMed PMID: 21881452.

26: Mauri MC, Rovera C, Paletta S, De Gaspari IF, Maffini M, Altamura AC. Aggression and psychopharmacological treatments in major psychosis and personality disorders during hospitalisation. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1631-5. doi: 10.1016/j.pnpbp.2011.05.008. Epub 2011 May 17. PubMed PMID: 21620921.

27: Parabiaghi A, D'Avanzo B, Tettamanti M, Barbato A; GiSAS Study Group. The GiSAS study: rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia. Contemp Clin Trials. 2011 Sep;32(5):675-84. doi: 10.1016/j.cct.2011.04.008. Epub 2011 Apr 30. PubMed PMID: 21554991.

28: Barbui C, Accordini S, Nosè M, Stroup S, Purgato M, Girlanda F,

Esposito E,  
Veronese A, Tansella M, Cipriani A; CHAT (Clozapine Haloperidol  
Aripiprazole  
Trial) Study Group. Aripiprazole versus haloperidol in combination  
with clozapine  
for treatment-resistant schizophrenia in routine clinical care: a  
randomized,  
controlled trial. J Clin Psychopharmacol. 2011 Jun;31(3):266-73.  
doi:  
10.1097/JCP.0b013e318219cba3. PubMed PMID: 21508849.

29: Colasanti A, Paletta S, Moliterno D, Mazzocchi A, Mauri MC,  
Altamura AC.  
Symptom dimensions as predictors of clinical outcome, duration of  
hospitalization, and aggressive behaviours in acutely hospitalized  
patients with  
psychotic exacerbation. Clin Pract Epidemiol Ment Health. 2010 Aug  
9;6:72-8. doi:  
10.2174/1745017901006010072. PubMed PMID: 21283648; PubMed Central  
PMCID:  
PMC3026339.

30: De Fazio P, Girardi P, Maina G, Mauri MC, Mauri M, Monteleone P,  
Perini GI,  
Perugi G, Rossi A. Aripiprazole in acute mania and long-term  
treatment of bipolar  
disorder: a critical review by an Italian working group. Clin Drug  
Investig.  
2010;30(12):827-841. doi: 10.2165/11584270-000000000-00000. Review.  
PubMed PMID:  
20923242.

31: Mauri MC, Paletta S, Moliterno D, Colasanti A, Altamura CA.  
Depressive  
dimension, clinical outcome, and duration of hospitalization in  
acute  
schizophrenia. Asian J Psychiatr. 2010 Sep;3(3):121-5. doi:  
10.1016/j.ajp.2010.08.004. PubMed PMID: 23051568.

32: Volonteri LS, Cerveri G, De Gaspari IF, Baldi ML, Rolandi ML,  
Papa P, Mauri  
MC, Mencacci C. Long-acting injectable risperidone and metabolic  
ratio: a  
possible index of clinical outcome in treatment-resistant  
schizophrenic patients.  
Psychopharmacology (Berl). 2010 Jul;210(4):489-97. doi:  
10.1007/s00213-010-1852-5. Epub 2010 Apr 27. PubMed PMID: 20422405.

33: Galderisi S, Davidson M, Kahn RS, Mucci A, Boter H, Gheorghe MD,



Rybakowski JK, Libiger J, Dollfus S, López-Ibor JJ, Peuskens J, Hranov LG, Fleischhacker WW; EUFEST group. Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study. *Schizophr Res.* 2009 Dec;115(2-3):104-14. doi: 10.1016/j.schres.2009.09.022. Epub 2009 Oct 12. PubMed PMID: 19822407.

34: Nosè M, Accordini S, Artioli P, Barale F, Barbui C, Beneduce R, Berardi D, Bertolazzi G, Biancosino B, Bisogno A, Bivi R, Bogetto F, Boso M, Bozzani A, Bucolo P, Casale M, Cascone L, Ciammella L, Cicolini A, Cipresso G, Cipriani A, Colombo P, Dal Santo B, De Francesco M, Di Lorenzo G, Di Munzio W, Ducci G, Erlicher A, Esposito E, Ferrannini L, Ferrato F, Ferro A, Fragomeno N, Parise VF, Frova M, Gardellin F, Garzotto N, Giambartolomei A, Giupponi G, Grassi L, Grazian N, Grecu L, Guerrini G, Laddomada F, Lazzarin E, Lintas C, Malchiodi F, Malvini L, Marchiaro L, Marsilio A, Mauri MC, Mautone A, Menchetti M, Migliorini G, Mollica M, Moretti D, Mulè S, Nicholau S, Nosè F, Occhionero G, Pacilli AM, Pecchioli S, Percudani M, Piantato E, Piazza C, Pontarollo F, Pycha R, Quartesan R, Rillosi L, Risso F, Rizzo R, Rocca P, Roma S, Rossattini M, Rossi G, Rossi G, Sala A, Santilli C, Saraò G, Sarnicola A, Sartore F, Scarone S, Sciarma T, Siracusano A, Strizzolo S, Tansella M, Targa G, Tasser A, Tomasi R, Travaglini R, Veronese A, Ziero S. Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. *Trials.* 2009 May 15;10:31. doi: 10.1186/1745-6215-10-31. PubMed PMID: 19445659; PubMed Central PMCID: PMC2689216.

35: Volonteri LS, Colasanti A, Cerveri G, Fiorentini A, De Gaspari IF, Mauri MC, Valli A, Papa P, Mencacci C. Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels. *J Psychopharmacol.* 2010 Aug;24(8):1193-9. doi:

10.1177/0269881109104863. Epub 2009  
Apr 30. PubMed PMID: 19406851.

36: Baldini M, Colasanti A, Orsatti A, Airaghi L, Mauri MC,  
Cappellini MD.  
Neuropsychological functions and metabolic aspects in subclinical  
hypothyroidism:  
the effects of L-thyroxine. Prog Neuropsychopharmacol Biol  
Psychiatry. 2009 Aug  
1;33(5):854-9. doi: 10.1016/j.pnpbp.2009.04.009. Epub 2009 Apr 21.  
PubMed PMID:  
19389454.

37: Mauri MC, Turner M, Volonteri LS, Medori R, Maier W. Dosing  
patterns in  
Europe: Efficacy and safety of risperidone long-acting injectable in  
doses of 25,  
37.5 and 50 mg. Int J Psychiatry Clin Pract. 2009;13(1):36-47. doi:  
10.1080/13651500802411979. PubMed PMID: 24946121.

38: Mauri MC, Moliterno D, Rossattini M, Colasanti A. Depression in  
schizophrenia: comparison of first- and second-generation  
antipsychotic drugs.  
Schizophr Res. 2008 Feb;99(1-3):7-12. Epub 2007 Dec 4. PubMed PMID:  
18055177.

39: Mauri MC, Gaietta M, Dragogna F, Valli I, Cerveri G, Marotta G.  
Hallucinatory  
disorder, an original clinical picture? Clinical and imaging data.  
Prog  
Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):523-30. Epub  
2007 Oct 25.  
PubMed PMID: 18037549.

40: Colasanti A, Natoli A, Moliterno D, Rossattini M, De Gaspari IF,  
Mauri MC.  
Psychiatric diagnosis and aggression before acute hospitalisation.  
Eur  
Psychiatry. 2008 Sep;23(6):441-8. Epub 2007 Nov 19. PubMed PMID:  
18024087.

41: Mauri MC, Volonteri LS, Fiorentini A, Pirola R, Bareggi SR. Two  
weeks'  
quetiapine treatment for schizophrenia, drug-induced psychosis and  
borderline  
personality disorder: a naturalistic study with drug plasma levels.  
Expert Opin  
Pharmacother. 2007 Oct;8(14):2207-13. PubMed PMID: 17927477.

42: Mauri MC, Colasanti A, Rossattini M, Volonteri LS, Dragogna F, Fiorentini A, Fiorentini A, Valli A, Papa P. Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels. *Pharmacopsychiatry*. 2007 May;40(3):89-92. PubMed PMID: 17541882.

43: Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. *Clin Pharmacokinet*. 2007;46(5):359-88. Review. PubMed PMID: 17465637.

44: Mauri MC, Valli I, Ferrari VM, Regispani F, Cerveri G, Invernizzi G. Hallucinatory disorder: preliminary data for a clinical diagnostic proposal. *Cogn Neuropsychiatry*. 2006 Sep;11(5):480-92. PubMed PMID: 17354083.

45: Mauri MC, Colasanti A, Rossattini M, Moliterno D, Baldi ML, Papa P. A single-blind, randomized comparison of olanzapine at a starting dose of 5 mg versus 20 mg in acute schizophrenia. *Clin Neuropharmacol*. 2006 May-Jun;29(3):126-31. PubMed PMID: 16772810.

46: Mauri MC, Volonteri LS, De Gaspari IF, Colasanti A, Brambilla MA, Cerruti L. Substance abuse in first-episode schizophrenic patients: a retrospective study. *Clin Pract Epidemiol Ment Health*. 2006 Mar 23;2:4. PubMed PMID: 16556300; PubMed Central PMCID: PMC1435752.

47: Mauri MC, Regispani F, Beraldo S, Volonteri LS, Ferrari VM, Fiorentini A, Invernizzi G. Patterns of clinical use of antipsychotics in hospitalized psychiatric patients. *Prog Neuropsychopharmacol Biol Psychiatry*. 2005 Jul;29(6):957-63. PubMed PMID: 16051409.

48: Mauri MC, Cerveri G, Volonteri LS, Fiorentini A, Colasanti A,

Manfré S,  
Borghini R, Pannacciulli E. Parasuicide and drug self-poisoning:  
analysis of the  
epidemiological and clinical variables of the patients admitted to  
the Poisoning  
Treatment Centre (CAV), Niguarda General Hospital, Milan. Clin Pract  
Epidemiol  
Ment Health. 2005 Apr 28;1(1):5. PubMed PMID: 15967050; PubMed  
Central PMCID:  
PMC1151597.

49: Mauri MC, Steinhilber CP, Marino R, Invernizzi E, Fiorentini A,  
Cerveri G,  
Baldi ML, Barale F. Clinical outcome and olanzapine plasma levels in  
acute  
schizophrenia. Eur Psychiatry. 2005 Jan;20(1):55-60. PubMed PMID:  
15642445.

50: Mauri M, Volonteri LS, Fiorentini A, Invernizzi G, Nerini T,  
Baldi M, Bareggi  
SR. Clinical outcome and plasma levels of clozapine and norclozapine  
in  
drug-resistant schizophrenic patients. Schizophr Res. 2004 Feb  
1;66(2-3):197-8.  
PubMed PMID: 15061256.

51: Mauri MC, Volonteri LS, Dell'Osso B, Regispani F, Papa P, Baldi  
M, Bareggi  
SR. Predictors of clinical outcome in schizophrenic patients  
responding to  
clozapine. J Clin Psychopharmacol. 2003 Dec;23(6):660-4. PubMed  
PMID: 14624196.

52: Mauri MC, Fiorentini A, Cerveri G, Volonteri LS, Regispani F,  
Malvini L,  
Boscatti L, Baido RL, Invernizzi G. Long-term efficacy and  
therapeutic drug  
monitoring of sertraline in major depression. Hum Psychopharmacol.  
2003  
Jul;18(5):385-8. PubMed PMID: 12858326.

53: Mauri MC, Volonteri LS, Fiorentini A, Dieci M, Righini A, Vita  
A. Efficacy of  
clozapine in a non-schizophrenic patient with psychogenic polydipsia  
and central  
pontine myelinolysis. Hum Psychopharmacol. 2002 Jul;17(5):253-5.  
PubMed PMID:  
12404683.

54: Mauri MC, Laini V, Cerveri G, Scalvini ME, Volonteri LS, Regispani F, Malvini L, Manfré S, Boscati L, Panza G. Clinical outcome and tolerability of sertraline in major depression: a study with plasma levels. *Prog Neuropsychopharmacol Biol Psychiatry*. 2002 Apr;26(3):597-601. PubMed PMID: 11999914.

55: Mauri MC, Boscati L, Volonteri LS, Scalvini ME, Steinhilber CP, Laini V, Zamberlan F. Predictive value of amino acids in the treatment of major depression with fluvoxamine. *Neuropsychobiology*. 2001;44(3):134-8. PubMed PMID: 11586053.

56: Ruggiero GM, Laini V, Mauri MC, Ferrari VM, Clemente A, Lugo F, Mantero M, Redaelli G, Zappulli D, Cavagnini F. A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. *Prog Neuropsychopharmacol Biol Psychiatry*. 2001 Jul;25(5):1049-59. PubMed PMID: 11444677.

57: Mauri MC, Laini V, Boscati L, Rudelli R, Salvi V, Orlandi R, Papa P. Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. *Eur Psychiatry*. 2001 Feb;16(1):57-63. PubMed PMID: 11246293.

58: Mauri MC, Laini V, Scalvini ME, Omboni A, Ferrari VM, Clemente A, Salvi V, Cerveri G. Gabapentin and the Prophylaxis of Bipolar Disorders in Patients Intolerant to Lithium. *Clin Drug Investig*. 2001 Mar;21(3):169-74. doi: 10.2165/00044011-200121030-00002. PubMed PMID: 27517546.

59: Mauri MC, Laini V, Barone R, Clemente A, Volonteri LS, Cerveri G, Steinhilber C, Fornier M. "Postpsychotic depression" and residual schizophrenia in a mental health hospital. *Encephale*. 2000 Nov-Dec;26(6):21-6. PubMed PMID: 11217534.

60: Mauri MC, Laini V, Scalvini ME, Volonteri LS, Ferrari MS, Panza G. Lithium safety in the prophylaxis of bipolar disorders: a study with plasma levels. Eur Rev Med Pharmacol Sci. 1999 Mar-Apr;3(2):63-9. PubMed PMID: 10827806.

61: Mauri MC, Bitetto A, Fabiano L, Laini V, Steinhilber C, Fornier M, Rafique F. Depressive symptoms and schizophrenic relapses: the effect of four neuroleptic drugs. Prog Neuropsychopharmacol Biol Psychiatry. 1999 Jan;23(1):43-54. PubMed PMID: 10368855.

62: Mauri MC, Laini V, Bitetto A, Boscati L, Scalvini M, Mapelli L, Rudelli R. Long term efficacy of paroxetine in major depression: A study with plasma levels. Int J Psychiatry Clin Pract. 1999;3(2):115-9. doi: 10.3109/13651509909024771. PubMed PMID: 24941093.

63: Mauri MC, Rudelli R, Bravin S, Gianetti S, Giuliani E, Guerrini A, Orlandi R, Invernizzi G. Clozapine metabolism rate as a possible index of drug-induced granulocytopenia. Psychopharmacology (Berl). 1998 Jun;137(4):341-4. PubMed PMID: 9676893.

64: Mauri MC, Ferrara A, Boscati L, Bravin S, Zamberlan F, Alecci M, Invernizzi G. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology. 1998;37(3):124-9. PubMed PMID: 9597668.

65: Mauri MC, Rudelli R, Vanni S, Panza G, Sicaro A, Audisio D, Sacerdote P, Panerai AE. Cholecystokinin, beta-endorphin and vasoactive intestinal peptide in peripheral blood mononuclear cells of drug-naive schizophrenic patients treated with haloperidol compared to healthy controls. Psychiatry Res. 1998 Mar 20;78(1-2):45-50. PubMed PMID: 9579701.

- 66: Mauri MC, Fabiano L, Bravin S, Ricci C, Invernizzi G. Schizophrenic patients before and after HIV infection: a case-control study. *Encephale*. 1997 Nov-Dec;23(6):437-41. PubMed PMID: 9488926.
- 67: Invernizzi G, Mauri MC, Waintraub L. Antidepressant efficacy in the treatment of dysthymia. *Eur Neuropsychopharmacol*. 1997 Oct;7 Suppl 3:S329-36. Review. PubMed PMID: 9405959.
- 68: Baldini IM, Vita A, Mauri MC, Amodei V, Carrisi M, Bravin S, Cantalamessa L. Psychopathological and cognitive features in subclinical hypothyroidism. *Prog Neuropsychopharmacol Biol Psychiatry*. 1997 Aug;21(6):925-35. PubMed PMID: 9380789.
- 69: Mauri MC, Bravin S, Bitetto A, Rudelli R, Invernizzi G. A risk-benefit assessment of sulpiride in the treatment of schizophrenia. *Drug Saf*. 1996 May;14(5):288-98. Review. PubMed PMID: 8800626.
- 70: Mauri MC, Rudelli R, Somaschini E, Roncoroni L, Papa R, Mantero M, Longhini M, Penati G. Neurobiological and psychopharmacological basis in the therapy of bulimia and anorexia. *Prog Neuropsychopharmacol Biol Psychiatry*. 1996 Feb;20(2):207-40. Review. PubMed PMID: 8861189.
- 71: Mauri MC, Bravin S, Fabiano L, Invernizzi G. [Effects of psychopathological components of the onset of Alzheimer's disease]. *Minerva Psichiatr*. 1995 Dec;36(4):203-7. Italian. PubMed PMID: 8721199.
- 72: Mauri MC, Bravin S, Fabiano L, Vanni S, Boscati L, Invernizzi G. Depressive symptoms and schizophrenia a psychopharmacological approach. *Encephale*. 1995 Sep-Oct;21(5):555-8. PubMed PMID: 8529564.

- 73: Mauri MC, Bravin S, Mantero M, Invernizzi G. Depression in schizophrenia: clinical and pharmacological variables. *Schizophr Res.* 1995 Feb; 14(3):261-2. PubMed PMID: 7766539.
- 74: Mauri MC, Leva P, Bravin S, Invernizzi G. [Psychopharmacological therapy in dementia]. *Minerva Psichiatr.* 1994 Sep;35(3):187-92. Review. Italian. PubMed PMID: 7968415.
- 75: Mauri MC, Leva P, Coppola MT, Altamura CA. L-sulpiride in young and elderly negative schizophrenics: clinical and pharmacokinetic variables. *Prog Neuropsychopharmacol Biol Psychiatry.* 1994 Mar;18(2):355-6. PubMed PMID: 8208984.
- 76: Mauri MC, Vita A, Giobbio GM, Ferrara A, Dieci M, Bitetto A, Altamura AC. Prediction of response to haloperidol in schizophrenia: neuroendocrine, neuromorphological and clinical variables. *Int Clin Psychopharmacol.* 1994 Spring;9(1):3-7. PubMed PMID: 8195579.
- 77: Altamura CA, Mauri MC, Ferrara A, Moro AR, D'Andrea G, Zamberlan F. Plasma and platelet excitatory amino acids in psychiatric disorders. *Am J Psychiatry.* 1993 Nov;150(11):1731-3. PubMed PMID: 8214185.
- 78: Mauri MC, Gianetti S, Pugnetti L, Altamura AC. Quazepam versus triazolam in patients with sleep disorders: a double-blind study. *Int J Clin Pharmacol Res.* 1993;13(3):173-7. PubMed PMID: 7901174.
- 79: Penati G, Panza G, Mantero M, Mauri MC. Paranoid ideation in geriatric depressed patients treated with alprazolam. *J Clin Psychopharmacol.* 1991 Feb;11(1):70-1. PubMed PMID: 2040718.
- 80: Altamura AC, Mauri MC, Regazzetti G, Coppola MT. [L-sulpiride in the



treatment of somatoform disturbances: a double-blind study with racemic sulpiride]. *Minerva Psichiatr.* 1991 Jan-Mar;32(1):25-9. Italian. PubMed PMID: 2056888.

81: Bareggi SR, Mauri M, Cavallaro R, Regazzetti MG, Moro AR. Factors affecting the clinical response to haloperidol therapy in schizophrenia. *Clin Neuropharmacol.* 1990;13 Suppl 1:S29-34. PubMed PMID: 2379182.

82: Mauri MC, Percudani M, Regazzetti MG, Altamura AC. Alternative prophylactic treatments to lithium in bipolar disorders. *Clin Neuropharmacol.* 1990;13 Suppl 1:S90-6. Review. PubMed PMID: 2116229.

83: Altamura AC, Mauri MC, Girardi T, Panetta B. Alcoholism and depression: a placebo controlled study with viloxazine. *Int J Clin Pharmacol Res.* 1990;10(5):293-8. PubMed PMID: 2079386.

84: Altamura AC, Mauri MC, Girardi T, Panetta B. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia. *Int J Clin Pharmacol Res.* 1990;10(4):223-8. PubMed PMID: 2079381.

85: Altamura CA, Colacurcio F, Mauri MC, Moro AR, De Novellis F. Haloperidol decanoate in chronic schizophrenia: a study of 12 months with plasma levels. *Prog Neuropsychopharmacol Biol Psychiatry.* 1990;14(1):25-35. PubMed PMID: 1967847.

86: Altamura AC, Mauri MC, De Novellis F, Percudani M, Vampini V. Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine. *Pharmacopsychiatry.* 1989 Nov;22(6):246-9. PubMed PMID: 2616635.

87: Altamura AC, Colacurcio F, Mauri MC, De Vanna M, Rigamonti R, Maj M, Veltro F, Pancheri P, Delle Chiaie R, Porta M, et al. [Controlled clinical study on the

effect of quazepam versus triazolam in patients with sleep disorders]. *Minerva Psichiatr.* 1989 Jul-Sep;30(3):159-64. Italian. PubMed PMID: 2691808.

88: Altamura AC, Mauri MC, Rudas N, Carpinello B, Montanini R, Perini M, Scapicchio PL, Hadjchristos C, Carucci G, Minervini M, et al. Clinical activity and tolerability of trazodone, mianserin, and amitriptyline in elderly subjects with major depression: a controlled multicenter trial. *Clin Neuropharmacol.* 1989;12 Suppl 1:S25-33; S34-7. PubMed PMID: 2663151.

89: Altamura AC, Mauri M, Cavallaro R, Regazzetti MG, Bareggi SR. Hydroxyhaloperidol and clinical outcome in schizophrenia. *Psychopharmacol Ser.* 1989;7:263-8. PubMed PMID: 2594731.

90: Altamura CA, Mauri MC, Coppola MT, Cazzullo CL. Delusional AIDS and depression. *Br J Psychiatry.* 1988 Aug;153:267-9. PubMed PMID: 3255453.

91: Altamura C, Mauri M, Cavallaro R, Colacurcio F, Gorni A, Bareggi S. Reduced haloperidol/haloperidol ratio and clinical outcome in schizophrenia: preliminary evidences. *Prog Neuropsychopharmacol Biol Psychiatry.* 1988;12(5):689-94. PubMed PMID: 3222450.

92: Altamura AC, Mauri MC, Colacurcio F, Scapicchio PL, Hadjchristos C, Carucci G, Minervini M, Montanini R, Perini M, Rudas N, et al. Trazodone in late life depressive states: a double-blind multicenter study versus amitriptyline and mianserin. *Psychopharmacology (Berl).* 1988;95 Suppl:S34-6. PubMed PMID: 3133712.

93: Altamura AC, Mauri MC, Mantero M, Brunetti M. Clonazepam/haloperidol combination therapy in schizophrenia: a double blind study. *Acta Psychiatr Scand.* 1987 Dec;76(6):702-6. PubMed PMID: 3327370.

- 94: Altamura AC, Mauri MC, Cavallaro R, Gorni A. Haloperidol metabolism and antipsychotic effect in schizophrenia. *Lancet*. 1987 Apr 4;1(8536):814-5. PubMed PMID: 2882227.
- 95: Altamura AC, De Novellis F, Mauri MC, Gomeni R. Plasma and brain pharmacokinetics of mianserin after single and multiple dosing in mice. *Prog Neuropsychopharmacol Biol Psychiatry*. 1987;11(1):23-33. PubMed PMID: 3602411.
- 96: Altamura AC, Mauri MC, Guercetti G, Cazzullo CL. Fluphenazine decanoate in acute and maintenance therapy of schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry*. 1987;11(5):613-23. PubMed PMID: 3122268.
- 97: Altamura AC, Mauri M, Guercetti G. Prophylactic treatment with mianserin, therapy adherence and plasma monitoring. A case report. *Acta Psychiatr Scand*. 1986 Aug;74(2):220-1. PubMed PMID: 3776669.
- 98: Altamura AC, Basile R, Mauri M, Cazzullo CL. [Valpromide (Depamide) in the treatment of acute psychotic states. Open clinical study]. *Acta Psychiatr Belg*. 1986 May-Jun;86(3):297-304. French. PubMed PMID: 2875606.
- 99: Altamura AC, Mauri MC, Guercetti G. Age, therapeutic "milieu" and clinical outcome in depressive patients treated with viloxazine: a study with plasma levels. *Prog Neuropsychopharmacol Biol Psychiatry*. 1986;10(1):67-75. PubMed PMID: 3704174.
- 100: Altamura AC, Mauri M. Plasma concentrations, information and therapy adherence during long-term treatment with antidepressants. *Br J Clin Pharmacol*. 1985 Dec;20(6):714-6. PubMed PMID: 4092003; PubMed Central PMCID: PMC1400844.
- 101: Milani GP, Bianchetti MG, Mazzoni MB, Triulzi F, Mauri MC, Agostoni C,

Fossali EF. Arterial hypertension and posterior reversible cerebral edema syndrome induced by risperidone. *Pediatrics*. 2014 Mar;133(3):e771-4. doi: 10.1542/peds.2013-1301. Epub 2014 Feb 24. PubMed PMID: 24567018.